Synergistic Combinations for Enhanced Ocular Delivery of Cell Permeant Therapeutics

The inventive concept integrates the patented ocular delivery technology with distinct technologies such as AI, IoT, blockchain, and new materials to create a more powerful system for treating retinal edema.

The original patent disclosed compositions and methods for the inhibition of diab, but it had limitations in terms of personalized treatment, real-time monitoring, and data management. The new inventive concept addresses these limitations by incorporating AI, IoT, blockchain, and new materials to create a synergistic combination that enhances the ocular delivery of cell permeant therapeutics.

The inventive concept comprises an ocular delivery device integrated with an AI-powered diagnostic module for detecting retinal edema in a patient. The device is further connected to a blockchain-based data management system that stores patient data and automates treatment protocols through smart contracts. Additionally, the system includes an IoT-enabled ocular delivery device that administers a conjugate comprising an X-linked inhibitor of apoptosis (XIAP)-baculoviral IAP repeat 3 (BIR3) to the patient. The conjugate is formulated with a cell-penetrating peptide and a new material with enhanced biocompatibility and biodegradability.

The new claims introduce the concept of synergistic combinations of distinct technologies to enhance the ocular delivery of cell permeant therapeutics, which is not obvious from the original patent. The integration of AI, IoT, blockchain, and new materials provides a non-obvious solution to the limitations of the original patent.

Alternative embodiments of the inventive concept could include the use of different AI algorithms, IoT protocols, or blockchain platforms. Variations could also include the integration of other distinct technologies, such as nanotechnology or gene editing, to further enhance the ocular delivery of cell permeant therapeutics.

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the area of retinal disease treatment. The integration of AI, IoT, blockchain, and new materials could provide a competitive advantage in the market and address the growing need for personalized and efficient treatment options.